Category: 3. Business

  • Google is a near-$4tn monument to monopoly power

    Google is a near-$4tn monument to monopoly power

    Stay informed with free updates

    Here’s a number to conjure with: $1.3tn. That’s the amount of market capitalisation Google parent Alphabet has added since September 2 — and it is equivalent to nearly double the combined gain in the rest of the so-called Magnificent 7.

    Why that date in particular? Because it’s when a US antitrust judge decided Google’s monopoly was no longer a potent threat in the age of AI. That decision left the company free to flex its muscles. With Alphabet’s market capitalisation edging closer to a colossal $4tn, the rest may soon be history.

    Google’s monopoly in online search — the judge did at least call it what it is — did indeed seem at risk for a while. The launch of ChatGPT in late 2022 threatened to drain the moat Google had created around itself. Analysts at Wells Fargo estimated in 2023 that the shift to “conversational” search, with inherently lower margins, could wipe 14 per cent off Alphabet’s operating profit.

    The reality has proved different. Users are searching more on Google, not less, and monetisation seems to be intact. It’s something like the principle of “induced demand” that explains why building more roads generates more traffic. Meanwhile, ChatGPT has, in recent months, handed back some of its market share gains to its larger rival.

    Last week, Google slew another foe: the belief that it’s an AI also-ran. The launch of its Gemini 3 model last Tuesday showed a clean pair of heels to OpenAI’s offerings on a range of so-called benchmarking tests, including reading what’s on a user’s screen, a key competency for creating AI “agents”. Salesforce chief Marc Benioff, a ChatGPT user, says he tried Google’s new offering and is “not going back”.

    Column chart of Year-on-year growth in Google's revenue-generating clicks (%) showing Click shift

    There are three reasons Google has been able to make this leap. One is that it houses some of the world’s most sophisticated research capabilities, thanks mostly to UK-based DeepMind, which it bought over a decade ago. A second reason is that Google is training its models on chips of its own making. Rivals still depend on whatever allocation of they can get from Nvidia, which dominates AI chips as Google dominates search.

    The third, and biggest reason? It’s a monopolist, and with that comes monopoly profit. Alphabet has made around $330bn in free cash flow over the past five years, according to LSEG. That gives it enormous leeway to invest for years in things that don’t obviously — and may never — produce revenue. Few companies can so easily accommodate massive spending on things peripheral to their core business. Certainly not OpenAI, which may make $20bn of revenue this year, if it is lucky.

    The bigger Google gets, the stronger. As its cloud business grows, now making up nearly a fifth of revenue, it becomes less vulnerable to hiccups in global advertising spend. Future revenue streams could come from selling its chips to other AI combatants like Meta Platforms. Some features of Gemini 3 suggest the company will become a stronger contender in the enterprise software market too.

    Of course, being huge on its own isn’t enough to sustain Google’s supremacy. It wouldn’t be where it is without smart ideas and products that people actually want to use. But the company’s impending $4tn valuation sends a strong message that anyone who thought AI would speed the end of tech’s most famous monopoly got it dead wrong.

    john.foley@ft.com

    Continue Reading

  • Ask the expert: Agricultural drones are reshaping farming | MSUToday

    Ask the expert: Agricultural drones are reshaping farming | MSUToday

    In the past decade, drones have become integral to many sectors of the economy. Now, they are rapidly transforming agriculture too, helping farmers grow their crops and changing the way farming is done.

    In a study published in Science, researchers at Michigan State University documented how agricultural drones have spread at extraordinary speed, first introduced in Asia then expanding to Latin America, North America and Europe.

    Ben Belton is a professor in the Department of Agricultural, Food and Resource Economics at the College of Agriculture and Natural Resources, and Leo Baldiga is a doctoral student in the Department of Geography, Environment and Spatial Sciences at the College of Social Science.

    Here, they explain how farms are putting drones to work, why drone use has accelerated so quickly, and what this development means for farmers and stakeholders.

    How have drones moved from hobby gadgets to major tools in global agriculture?

    Drones have become integrated into everyday life over the past decade — in sectors as diverse as entertainment, health care and construction. They also have begun to transform the way people grow food.

    Just a few years ago, agricultural drones were expensive, small and difficult to use, limiting their appeal to farmers. In contrast, today’s models can be flown immediately after purchase and carry loads weighing up to 220 pounds — the weight of two sacks of fertilizer.

    Agricultural drones are now akin to flying tractors — multifunctional machines that can perform numerous tasks using different hardware attachments. Common uses for drones on farms include spraying crops, spreading fertilizer, sowing seeds, transporting produce, dispensing fish feeds, painting greenhouses, monitoring livestock locations and well-being, mapping field topography and drainage, and measuring crop health. This versatility makes drones valuable for growing numerous crops and on farms of all sizes.

    Where are agricultural drones used, and why has their use increased so quickly?

    In a new study published in the journal Science, we show that use of agricultural drones has spread extremely rapidly around the world. In our research as social scientists studying agriculture and rural development, we set out to document where agricultural drones have taken off around the world, what they are doing and why they have traveled so far so fast. We also explored what these changes mean for farmers, the environment, the public and governments.

    Historically, most agricultural technology — tractors, for example — has spread from high-income countries to middle- and then lower-income ones over the course of many decades. Drones partially reversed and dramatically accelerated this pattern, diffusing first from East Asia to Southeast Asia, then to Latin America, and finally to North America and Europe. Their use in higher-income regions is more limited but is accelerating rapidly in the U.S.

    China leads the world in agricultural drone manufacturing and adoption. In 2016, a Chinese company introduced the first agriculture-specific quadcopter model. There are now more than 250,000 agricultural drones reported to be in use there. Other middle-income countries have also been enthusiastic adopters. For instance, drones were used on 30% of Thailand’s farmland in 2023, up from almost none in 2019, mainly for spraying pesticides and spreading fertilizers.

    In the U.S., the number of agricultural drones registered with the Federal Aviation Administration leaped from about 1,000 in January 2024 to around 5,500 in mid-2025. Industry reports suggest those numbers substantially underreport U.S. drone use because some owners avoid the complex registration process. Agricultural drones in the U.S. are used mainly for spraying crops such as corn and soybeans, especially in areas that are difficult to reach with tractors or crop-dusting aircraft.

    What risks and benefits do drones bring for farmers and the environment?

    Shifting from applying chemicals with backpack sprayers to drones substantially reduces the risk of direct exposure to toxins for farmers and farmworkers. However, because drones usually spray from a height of at least 6 feet, if used improperly, they can spread droplets containing pesticides or herbicides to neighboring farms, waterways or bystanders. That can damage crops and endanger people and nature.

    Drones spray and spread fertilizers and seeds evenly and efficiently so that less is wasted. They may also reduce damage to crops in the field and consume less energy than large farm machines such as tractors.

    Are drones saving labor or displacing it?

    Drones save farmers time and money. They reduce the need for smallholders — people who farm less than 5 acres, who account for 85% of farms globally — to do dangerous and tiring manual spraying and spreading work on their own farms. They also remove the need to hire workers to do the same. By eliminating some of the last remaining physically demanding work in farming, drones also may help make agriculture more attractive to rural youth, who are often disillusioned with the drudgery of traditional farming. In addition, drones create new skilled employment opportunities in rural areas for pilots, many of whom are young people.

    On the downside, using drones could displace workers who currently earn a living from crop spraying. For instance, according to one estimate from China, drones can cover between 10 and 25 acres of farmland per hour when spraying pesticides. That is equivalent to the effort of between 30 and 100 workers spraying manually. Governments may need to find ways to help displaced workers find new jobs.

    What could agricultural drones mean for future food production?

    Drones may increase the amount of food that can be produced on each acre of land, while reducing the amount of resources needed to do so. This outcome is a holy grail for agricultural scientists, who refer to it as “sustainable intensification.”

    However, much of the evidence so far on yield gains from drone-assisted farming is anecdotal, or based on small studies or industry reports.

    The drone revolution is reshaping farming faster than almost any technology before it. In just five years, millions of farmers around the world have embraced drones. Early signs point to big benefits: greater efficiency, safer working conditions and improved rural livelihoods. But the full picture isn’t clear yet.


    Continue Reading

  • Submit Abstract for ATLS Global Symposium and Showcase Your Trauma Program’s Achievements

    Be part of a global conversation about how trauma education—especially the ACS Advanced Trauma Life Support® (ATLS®) program—is saving lives and strengthening trauma systems in every corner of the world by submitting a poster abstract for presentation at the 2026 ATLS Global Symposium, March 13–15 in Birmingham, Alabama.

    The deadline to submit is December 1, 2025.

    By presenting a poster, you can:

    • Showcase your program’s global relevance and local achievements.
    • Demonstrate how ATLS continues to evolve and empower care teams worldwide.
    • Gain recognition among international peers and trauma leaders.
    • Spark dialogue and collaboration across borders and disciplines.

    Review the Call for Posters for instructions on poster categories (Scientific and Best Practices Category) and submission and presenter requirements.

    Submit your poster now through the Global Symposium Poster Submission Form

    Continue Reading

  • Strong Revenue Growth and Strategic …

    Strong Revenue Growth and Strategic …

    This article first appeared on GuruFocus.

    • Revenue: $9.7 billion, a 2.4% increase year-over-year.

    • Adjusted Operating Income Rate: 4%, 30 basis points better than expected.

    • Adjusted Earnings Per Share: Increased 11% year-over-year to $1.40.

    • Comparable Sales Growth: 2.7%, exceeding expectations.

    • Domestic Revenue: $8.9 billion, a 2.1% increase driven by 2.4% comparable sales growth.

    • Online Revenue: $2.8 billion, a 3.5% increase on a comparable basis, representing 31.8% of domestic revenue.

    • International Revenue: $794 million, a 6.1% increase driven by 6.3% comparable sales growth.

    • Domestic Gross Profit Rate: Decreased by 30 basis points to 23.3%.

    • International Gross Profit Rate: Increased by 30 basis points to 22.8%.

    • SG&A Expenses: Domestic adjusted SG&A decreased by $4 million.

    • Shareholder Returns: $802 million returned through dividends and share repurchases year-to-date.

    • Fourth Quarter Comparable Sales Guidance: Expected range of down 1% to up 1%.

    • Full Year Revenue Guidance: $41.65 billion to $41.95 billion.

    • Full Year Comparable Sales Growth Guidance: 0.5% to 1.2%.

    • Full Year Adjusted Operating Income Rate Guidance: Approximately 4.2%.

    • Full Year Adjusted Diluted EPS Guidance: $6.25 to $6.35.

    Release Date: November 25, 2025

    For the complete transcript of the earnings call, please refer to the full earnings call transcript.

    • Best Buy Co Inc (NYSE:BBY) reported strong third-quarter results with revenue of $9.7 billion, an adjusted operating income rate of 4%, and an 11% year-over-year increase in adjusted earnings per share to $1.40.

    • The company achieved better-than-expected comparable sales growth of 2.7%, driven by strong sales in computing, gaming, and mobile phones.

    • Online sales increased for the fourth consecutive quarter, supported by higher traffic and increased customer adoption of the Best Buy app.

    • The launch of the Best Buy marketplace has been successful, with over 1,000 sellers and 11 times more SKUs available online, contributing positively to gross profit rates.

    • Best Buy Co Inc (NYSE:BBY) continues to innovate with new in-store experiences and partnerships, such as immersive showcase areas for AI glasses and collaborations with IKEA, enhancing customer engagement and satisfaction.

    • The company experienced declines in the home theater, appliance, and drone categories, which partially offset growth in other areas.

    • Best Buy Co Inc (NYSE:BBY) anticipates a decline in fourth-quarter gross profit rate due to increased promotional investments and lower product margin rates.

    • The appliance market remains challenging, with a high percentage of single-unit purchases and a focus on duress customers, impacting promotional effectiveness.

    • Despite positive momentum, the fourth-quarter comparable sales outlook is expected to be in the range of down 1% to up 1%, reflecting potential challenges in maintaining growth.

    • The company recorded pretax noncash asset impairments of $192 million related to Best Buy Health, indicating pressures in the Medicaid and Medicare Advantage markets.

    Q: Can you discuss the puts and takes on Q4 guidance, especially in terms of sales and profit expectations? A: Matthew Bilunas, CFO, explained that the high end of Q4 sales guidance is similar to previous expectations, with a slight adjustment on the low end. The EBIT expectations were slightly lowered due to rate pressure and adjusted revenue expectations, but overall, the guidance remains consistent with prior discussions.

    Q: How is the adoption of products like the Nintendo Switch 2 and iPhone affecting future momentum? A: Matthew Bilunas noted that computing and mobile phones are expected to continue growing due to replacement needs and innovation. The Nintendo Switch 2 will support growth in Q4, but other consoles may slow due to their lifecycle stages. Improvements in TV trends and marketplace initiatives are also expected to contribute positively.

    Q: What is driving the deceleration in Q4 outlook despite momentum from Q3? A: Matthew Bilunas highlighted that Q3 benefited from strong back-to-school and October sales, but Q4 faces tougher comparisons. Categories like gaming and wearables may not grow at the same pace as in Q3, and the holiday season’s unpredictability requires a range of scenarios for planning.

    Q: How is the new marketplace performing, and what challenges have you encountered? A: Corie Barry, CEO, expressed satisfaction with the marketplace launch, noting over 1,000 sellers and 11x more SKUs. Early indicators are positive, with high unit sales in accessories and small appliances, lower return rates, and strong customer experience metrics. However, the ramp is still early, and the focus is on scaling through Q4.

    Q: Can you provide more details on the loyalty program’s performance and future plans? A: Corie Barry stated that the membership program is crucial, with nearly 8 million paid members. The focus is on driving value through personalized promotions and unique offers, such as discounts on NFL Sunday tickets. The goal is to increase engagement, share of wallet, and support the ads business.

    Q: How are you planning store investments for the coming year? A: Corie Barry emphasized the importance of stores as crucial assets for experiences and fulfillment. Investments focus on store look and feel, vendor partnerships, and exploring smaller format stores. The goal is to ensure stores reflect immersive experiences and meet customer expectations.

    Q: How are tariffs affecting pricing and average unit retail (AUR)? A: Matthew Bilunas explained that tariffs are included in pricing, but the promotional nature of the industry and product mix changes can mute their impact on AUR. The focus remains on offering products at every price point to meet customer budgets.

    Q: How does vendor-supported labor in stores impact customer engagement? A: Corie Barry described the flexible labor model, which includes vendor-supported labor, as enhancing customer engagement. The model allows for specialized expertise while maintaining Best Buy’s service culture, improving customer interactions and satisfaction.

    Q: What are the prospects for Agentic Commerce and instant checkout? A: Corie Barry indicated a fast timeline for integration, focusing on customer experience and ensuring seamless transactions, especially for scheduled deliveries and services. The goal is to enhance brand presence and customer engagement through Agentic tools.

    Q: How are you managing SG&A expenses amid sales growth? A: Matthew Bilunas noted that SG&A favorability in Q3 was due to higher sales leverage, lower technology and labor spend, and smaller settlements. The focus remains on operational efficiencies and cost reductions to offset pressures and drive profitability.

    For the complete transcript of the earnings call, please refer to the full earnings call transcript.

    Continue Reading

  • Gemini 3 — and the custom chips that power it — is a wake up call for AI investors

    Gemini 3 — and the custom chips that power it — is a wake up call for AI investors

    Continue Reading

  • Oil falls as Ukraine signals support for framework of Russia peace deal – Reuters

    1. Oil falls as Ukraine signals support for framework of Russia peace deal  Reuters
    2. WTI crude weakens near $58.5 ahead of major geopolitical decisions  Traders Union
    3. Oil News: Traders Fade Bounce in Crude Oil as Inventory Fears Hit Oil Outlook  FXEmpire
    4. Oil Slips as Oversupply Takes Centre Stage  VT Markets
    5. Crude Oil Forecast: WTI Nears Multi-Year Lows on Ukraine Peace Hopes  FOREX.com

    Continue Reading

  • S&P Global puts Under Armour's ratings on downgrade watch – Reuters

    1. S&P Global puts Under Armour’s ratings on downgrade watch  Reuters
    2. Under Armour, Inc. (NYSE:UAA) Receives Consensus Rating of “Reduce” from Analysts  MarketBeat
    3. Brokers Issue Forecasts for Under Armour Q4 Earnings  MarketBeat
    4. William Blair Forecasts Under Armour Q2 Earnings  MarketBeat
    5. Under Armour (NYSE:UAA) Hits New 1-Year Low – Here’s What Happened  MarketBeat

    Continue Reading

  • Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

    Notes

    Gastric and gastroesophageal junction cancers
    Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-highest leading cause of cancer mortality.1 Nearly one million new patients were diagnosed with gastric cancer in 2022, with approximately 660,000 deaths reported globally.1 In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.3 In 2024, there were roughly 43,000 drug-treated patients in the US, EU and Japan in early-stage and locally advanced gastric or GEJ cancer.2 Approximately 62,000 patients in these regions are expected to be newly diagnosed in this setting by 2030.4

    GEJ cancer is a type of gastric cancer that arises from and spans the area where the oesophagus connects to the stomach.5

    Disease recurrence is common in patients with resectable gastric cancer despite undergoing surgery with curative intent and treatment with neoadjuvant/adjuvant chemotherapy.6 Approximately one in four patients with gastric cancer who undergo surgery develop recurrent disease within one year, and the five-year survival rate remains poor, with less than half of patients alive at five years.6-7

    MATTERHORN
    MATTERHORN is a randomised, double-blind, placebo-controlled, multi-centre, global Phase III trial evaluating Imfinzi as perioperative treatment for patients with resectable Stage II-IVA gastric and GEJ cancers. Perioperative therapy includes treatment before and after surgery, also known as neoadjuvant/adjuvant therapy. In the trial, 948 patients were randomised to receive a 1500mg fixed dose of Imfinzi plus FLOT chemotherapy or placebo plus FLOT chemotherapy every four weeks for two cycles prior to surgery. This was followed by Imfinzi or placebo every four weeks for up to 12 cycles after surgery (including two cycles of Imfinzi or placebo plus FLOT chemotherapy and 10 additional cycles of Imfinzi or placebo monotherapy).

    In the MATTERHORN trial, the primary endpoint is EFS, defined as time from randomisation until the date of one of the following events (whichever occurred first): RECIST (version 1.1, per blinded independent central review assessment) progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period; RECIST progression/recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Key secondary endpoints include pathologic complete response rate, defined as the proportion of patients who have no detectable cancer cells in resected tumour tissue following neoadjuvant therapy, and OS. The trial enrolled participants in 176 centres in 20 countries, including in the US, Canada, Europe, South America and Asia.

    Imfinzi
    Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

    In GI cancer, Imfinzi is approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer (BTC) and in combination with Imjudo (tremelimumab) in unresectable hepatocellular carcinoma (HCC). Imfinzi is also approved as a monotherapy in unresectable HCC in Japan and the EU. 

    In addition to its indications in GI cancers, Imfinzi is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy (CRT). Additionally, Imfinzi is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of Imjudo and chemotherapy for the treatment of metastatic NSCLC. Imfinzi is also approved for limited-stage small cell lung cancer (SCLC) in patients whose disease has not progressed following concurrent platinum-based CRT; and in combination with chemotherapy for the treatment of extensive-stage SCLC.

    Perioperative Imfinzi in combination with neoadjuvant chemotherapy is approved in the US, EU, Japan and other countries for patients with muscle-invasive bladder cancer based on results from the NIAGARA Phase III trial. Additionally, in May 2025, Imfinzi added to Bacillus Calmette-Guérin induction and maintenance therapy met the primary endpoint of disease-free survival for patients with high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial.

    Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease only in the US and EU). Imfinzi in combination with chemotherapy followed by Lynparza (olaparib) and Imfinzi is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in the EU and Japan.

    Since the first approval in May 2017, more than 414,000 patients have been treated with Imfinzi. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, bladder cancer, breast cancer, ovarian cancer and several GI cancers.

    AstraZeneca in GI cancers
    AstraZeneca has a broad development programme for the treatment of GI cancers across several medicines and a variety of tumour types and stages of disease. In 2022, GI cancers collectively represented approximately 5 million new cancer cases leading to approximately 3.3 million deaths.8

    Within this programme, the Company is committed to improving outcomes in gastric, liver, biliary tract, oesophageal, pancreatic, and colorectal cancers.

    In addition to its indications in BTC and HCC, Imfinzi is being assessed in combinations, including with Imjudo, in liver, oesophageal and gastric cancers in an extensive development programme spanning early to late-stage disease across settings.

    Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), is approved in the US and several other countries for HER2-positive advanced gastric cancer. Enhertu is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

    Lynparza, a first-in-class PARP inhibitor, is approved in the US and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. inside the US and Canada).

    The Company is also assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in combination with chemotherapy as an adjuvant therapy in BTC, in combination with bevacizumab with or without Imjudo as a 1st-line treatment in patients with advanced HCC, and as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic gastric and GEJ cancers. Rilvegostomig is also being evaluated in combination with Enhertu in previously untreated, HER2-expressing, locally advanced or metastatic BTC.

    AstraZeneca is advancing multiple modalities that provide complementary mechanisms for targeting Claudin 18.2, a promising therapeutic target in gastric cancer. These include sonesitatug vedotin, a potential first-in-class ADC licensed from KYM Biosciences Inc., currently in Phase III development; AZD5863, a novel Claudin 18.2/CD3 T-cell engager bispecific antibody licensed from Harbour Biomed in Phase I development; and AZD4360, an antibody drug conjugate, currently being evaluated in a Phase I/II trial in patients with advanced solid tumours.

    In early development, AstraZeneca is developing C-CAR031 / AZD7003, a Glypican 3 (GPC3) armoured CAR T, in HCC. C-CAR031 / AZD7003is being co-developed with AbelZeta in China where it is under evaluation in an IIT.

    AstraZeneca in immuno-oncology (IO)
    AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours.

    AstraZeneca strives to redefine cancer care and help transform outcomes for patients with Imfinzi as a monotherapy and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers.

    AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure.

    AstraZeneca in oncology
    AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

    The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

    AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

    AstraZeneca
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

    Continue Reading

  • London Transit bus workers postpone strike action

    London Transit bus workers postpone strike action

    Getty Images Commuters queue for buses outside Victoria underground train station. It is a busy day with a sea of people outside the bus. A red North Finchley 13 bus has arrived at the stop. Getty Images

    More than 350 staff at London Transit were due to walk out on 26, 27 and 28 November

    Three more days of strike action by west London bus workers have been postponed pending further talks next week.

    More than 350 staff at London Transit were due to walk out on 26, 27 and 28 November. Drivers, engineers and store workers based at the Westbourne Park depot are unhappy with a below-inflation pay rise offered by the company’s parent firm, First Bus London.

    The same Unite union members previously took part in industrial action on 14, 17 and 18 November.

    First Bus London said: “We’re pleased that, following positive discussions, the planned strike action has been cancelled and that further talks with Unite will continue.”

    It added: “Industrial action causes significant disruption for Londoners who rely on our services and for our colleagues, so we welcome this outcome.”

    Unite has agreed to attend a meeting with conciliation service Acas and London Transit on 2 December in an effort to resolve the dispute.

    Transport for London confirmed that services were expected to run as normal in the coming days.

    ‘Utter disregard’

    Unite previously requested an above-inflation pay offer with full back pay for all employees, demands it says have not yet been met.

    Unite’s general secretary Sharon Graham said: “This is disgraceful behaviour from a company making millions from London bus passengers.

    “It shows an utter disregard for its workers and the hard work they do day in, day out.

    “Our members won’t stand for such behaviour and Unite will back them all the way in this dispute with a company that has a history of anti-worker behaviour.”

    Routes affected during the strike would have included 13, 23, 31, N31, 218, 295 and 452.

    More related to this story

    Continue Reading

  • Acting Chairman Caroline D. Pham Seeks Nominations for CFTC CEO Innovation Council by December 8

    Acting Chairman Caroline D. Pham Seeks Nominations for CFTC CEO Innovation Council by December 8

    — Commodity Futures Trading Commission Acting Chairman Caroline D. Pham is seeking nominations for the CFTC CEO Innovation Council. The deadline for submissions is December 8. Under Acting Chairman Pham’s leadership, the CFTC has led rapid advancements on innovation and market structure, including the Crypto CEO Forum, prediction markets, perpetual contracts, and 24/7 trading. The CFTC’s Crypto Sprint to implement the President’s Working Group on Digital Asset Markets report recommendations is targeted to continue through August 2026 and includes listed spot crypto trading, tokenized collateral and stablecoins, and rulemaking to enable the use of blockchain technology and market infrastructure. 

    “The U.S. is leading a new era in market structure, and the CFTC is at the forefront of this renaissance accelerated by innovation and technology,” said Acting Chairman Pham. “The CFTC stands ready to carry out our mission over expanded markets and products, including crypto and digital assets, and ensure our markets remain vibrant and resilient while protecting all participants. In order to hit the ground running, it is critical that the CFTC drives public engagement with the support of expert industry leaders and visionaries who are building the future. That is why today I am calling upon CEOs to join us in shaping responsible regulations that will lay the foundation for America’s Golden Age of Innovation.”

    Acting Chairman Pham invites members of the public to nominate individuals for the CEO Innovation Council and propose potential topics to prioritize. Each nomination submission should include relevant information about the nominee, such as the individual’s name, title, and organizational affiliation as well as information that supports the individual’s qualifications for the CEO Innovation Council. The submission should also include suggestions for potential topics to prioritize as well as the name and email or mailing address of the person nominating the individual. Submission of a nomination is not a guarantee of selection for the CEO Innovation Council.

    CEO Innovation Council nominations and potential topics should be emailed to [email protected]. Please use the subject ‘‘CEO Innovation Council Nomination’’ for submissions.

    Continue Reading